The recommended dosage of Zin-Ulix White Injection, i.e. Polyethylene Glycolized Recombinant Human Granulocyte Stimulating Factor Injection, is 100 μg/kg per subcutaneous injection, subject to medical advice.
1. Polyethylene Glycolized Recombinant Human Granulocyte Stimulating Factor Injection is administered as a subcutaneous injection at 100 μg/kg of body weight, 48 hours after the end of chemotherapy drug administration, once per chemotherapy cycle. This dose should not be used in children.
2.This product is indicated for use to reduce the incidence of febrile neutropenia-induced infections in patients with non-myeloid malignancies receiving antineoplastic agents when clinically significant febrile neutropenic myelosuppression may occur.
This product is not intended for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
3. Adverse reactions of this product include bone pain, arthralgia, muscle pain, elevated transaminases, elevated blood creatinine and urea nitrogen, malaise, fever, palpitations, insomnia, dizziness, etc. Rarely, there are adverse reactions such as splenic rupture, severe allergic reactions, acute respiratory distress syndrome.
4. This product is contraindicated in those who are allergic to this product, to preparations expressed by Escherichia coli, and in those with severe cardiac, pulmonary, hepatic, renal, and functional disorders. When it is necessary to use Generic Polyethylene Glycolized Recombinant Human Granulocyte Stimulating Factor Injection, it should be used reasonably under the guidance of a doctor.